Natl. Institute on Drug Abuse Director Charles Schuster told a meeting of the Natl. Advisory Council on Drug Abuse Sept. 16 that an NIAD grantee, Tony Yaksh, Mayo Clinic, "has shown that an opioid peptide, D-Ala2-DO-Leu5-enkephalin (DADL), binds to the brain's delta opiate receptor to produce analgesia in cancer patients." Schuster said the discovery is "an important step toward the development of a non-addictive pain-killer that could replace morphine".
You may also be interested in...
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
Execs On The Move: Medical Microinstruments Gets New CEO; Changes At iRhythm; Aethlon Makes A Promotion
Corindus Vascular Robotics CEO made a lateral move to Medical Microinstruments; iRhythm hires a new CEO, while the former CEO stays on as a director; Aethlon promotes a director to chief business officer; and more.